Context Therapeutics Inc. (CNTX) stock
CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.18−0.02 (-8.69%)
Close on Nov 13, 2026Market cap $16.61MP/E –Yield –
Context Therapeutics cash
Cash and short-term investments held at the end of each period.
Context Therapeutics's cash was $34.41M at Sep 30, 2026. For fiscal 2025 it was $66.00M, down 30.1% from the year before. The highest annual figure on record is $94.43M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.00M | -30.1% |
| FY2024 | Dec 31, 2024 | $94.43M | +553.5% |
| FY2023 | Dec 31, 2023 | $14.45M | -59.3% |
| FY2022 | Dec 31, 2022 | $35.50M | -28.6% |
| FY2021 | Dec 31, 2021 | $49.69M | +14469.0% |
| FY2020 | Dec 31, 2020 | $341.04K | +50.5% |
| FY2019 | Dec 31, 2019 | $226.60K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $34.41M | -55.3% |
| Q2 FY2026 | Jun 30, 2026 | $42.99M | -48.5% |
| Q1 FY2026 | Mar 31, 2026 | $54.53M | -39.0% |
| Q4 FY2025 | Dec 31, 2025 | $66.00M | -30.1% |
| Q3 FY2025 | Sep 30, 2025 | $76.94M | -9.3% |
| Q2 FY2025 | Jun 30, 2025 | $83.52M | -17.7% |
| Q1 FY2025 | Mar 31, 2025 | $89.35M | +785.6% |
| Q4 FY2024 | Dec 31, 2024 | $94.43M | +553.5% |
| Q3 FY2024 | Sep 30, 2024 | $84.80M | +291.2% |
| Q2 FY2024 | Jun 30, 2024 | $101.54M | +303.9% |
| Q1 FY2024 | Mar 31, 2024 | $10.09M | -66.1% |
| Q4 FY2023 | Dec 31, 2023 | $14.45M | -59.3% |
| Q3 FY2023 | Sep 30, 2023 | $21.68M | -45.0% |
| Q2 FY2023 | Jun 30, 2023 | $25.14M | -41.4% |
| Q1 FY2023 | Mar 31, 2023 | $29.77M | -34.9% |
| Q4 FY2022 | Dec 31, 2022 | $35.50M | -28.6% |
| Q3 FY2022 | Sep 30, 2022 | $39.43M | +9306.4% |
| Q2 FY2022 | Jun 30, 2022 | $42.92M | +3254.0% |
| Q1 FY2022 | Mar 31, 2022 | $45.73M | +2654.2% |
| Q4 FY2021 | Dec 31, 2021 | $49.69M | +14469.0% |
| Q3 FY2021 | Sep 30, 2021 | $419.15K | +150.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.28M | +464.7% |
| Q1 FY2021 | Mar 31, 2021 | $1.66M | – |
| Q4 FY2020 | Dec 31, 2020 | $341.04K | – |
| Q3 FY2020 | Sep 30, 2020 | $167.06K | – |
| Q4 FY2019 | Dec 31, 2019 | $226.60K | – |
See a number that looks wrong?